| P2093 | author name string | Wim Vandenberghe | |
| | Jelle Demeestere | |
| P2860 | cites work | Huntington disease | Q48465200 |
| | Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study | Q48608882 |
| | Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease | Q48774077 |
| | Unified Huntington's disease rating scale: Reliability and consistency | Q57422462 |
| | Therapeutic interventions for symptomatic treatment in Huntington's disease | Q24239893 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 |
| | Stem and progenitor cells: the premature desertion of rigorous definitions | Q28210270 |
| | Huntington's disease | Q28284355 |
| | Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes | Q28302701 |
| | Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue | Q28506834 |
| | Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease | Q28588314 |
| | Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice | Q28594828 |
| | Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 |
| | The functional anatomy of basal ganglia disorders | Q29617461 |
| | Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease | Q30493159 |
| | AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease | Q30549911 |
| | Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. | Q31118947 |
| | Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes | Q31158487 |
| | Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease | Q33533774 |
| | Differential loss of striatal projection neurons in Huntington disease | Q33637273 |
| | Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. | Q33713689 |
| | RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model | Q33936969 |
| | Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study | Q33994217 |
| | Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia | Q34554762 |
| | Pallidal deep-brain stimulation in primary generalized or segmental dystonia | Q34580380 |
| | Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease | Q34695123 |
| | Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi | Q34768688 |
| | Antisense oligonucleotide therapy for neurodegenerative disease. | Q34830633 |
| | Progress and challenges in RNA interference therapy for Huntington disease | Q34996510 |
| | GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case | Q45289694 |
| | Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. | Q45289792 |
| | Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus | Q45289913 |
| | Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea | Q45291572 |
| | Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease | Q45292300 |
| | Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation | Q45292873 |
| | A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. | Q45293098 |
| | Bilateral globus pallidus stimulation for Huntington's disease | Q45294322 |
| | Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations | Q45294365 |
| | Safety of intrastriatal neurotransplantation for Huntington's disease patients | Q45295583 |
| | Striatal transplantation in a transgenic mouse model of Huntington's disease | Q45297047 |
| | In vivo magnetic resonance spectroscopy of human fetal neural transplants | Q45298655 |
| | Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo | Q45299326 |
| | Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease | Q45299926 |
| | Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report | Q45300029 |
| | Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 |
| | rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse | Q45300326 |
| | Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results | Q45300364 |
| | Inhibition of Huntington synthesis by antisense oligodeoxynucleotides | Q45301678 |
| | Internal globus pallidotomy in dystonia secondary to Huntington's disease | Q45301763 |
| | Motor and cognitive improvements in patients with Huntington's disease after neural transplantation | Q45301920 |
| | Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease | Q45302126 |
| | Anterior cingulate cortical transplantation in transgenic Huntington's disease mice | Q45304732 |
| | Neural transplantation in Huntington disease: long-term grafts in two patients | Q45305355 |
| | Bilateral human fetal striatal transplantation in Huntington's disease. | Q45305502 |
| | Fetal striatal homotransplantation for Huntington's disease: first two case reports. | Q45307105 |
| | Antisense gene therapy for neurodegenerative disease? | Q45881518 |
| | Progress in antisense technology. | Q46033759 |
| | ??? | Q64781363 |
| | Neural transplantation in patients with Huntington's disease | Q35214572 |
| | Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease | Q35575249 |
| | Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology | Q35579484 |
| | Neurotrophic factors in Huntington's disease | Q35618345 |
| | Cell therapy in Huntington's disease. | Q36045364 |
| | Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits | Q36089160 |
| | Intrabodies as drug discovery tools and therapeutics | Q36175301 |
| | Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin | Q36677547 |
| | Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate | Q36696707 |
| | Stem cell transplantation for Huntington's disease. | Q36701470 |
| | Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. | Q36954944 |
| | Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice | Q37131550 |
| | A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions | Q37178480 |
| | The current clinical management of Huntington's disease | Q37200714 |
| | Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments | Q37209427 |
| | Rodent genetic models of Huntington disease | Q37220633 |
| | Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration | Q37268805 |
| | Lost in a jungle of evidence: we need a compass | Q37322986 |
| | Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. | Q37494307 |
| | Biochemical principles of small RNA pathways | Q37703232 |
| | Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea | Q39109797 |
| | Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. | Q39728016 |
| | Slowed progression in models of Huntington disease by adipose stem cell transplantation | Q39770706 |
| | Sustained effects of nonallele-specific Huntingtin silencing | Q39866098 |
| | BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. | Q39932912 |
| | Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity | Q39943981 |
| | Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. | Q40397746 |
| | Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. | Q40462605 |
| | Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis | Q40585913 |
| | Antisense downregulation of mutant huntingtin in a cell model. | Q40641130 |
| | Antisense-mediated down-regulation of the human huntingtin gene | Q40854760 |
| | Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia | Q41174270 |
| | Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients | Q42559350 |
| | Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation | Q43212739 |
| | Viral delivery of recombinant short hairpin RNAs | Q43546899 |
| | High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo | Q44162261 |
| | Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. | Q44213139 |
| | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 |
| | Can lesions of GPe correct HD deficits? | Q44774622 |
| | RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. | Q44964949 |
| | Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice | Q45288789 |
| | Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. | Q45289044 |
| P433 | issue | 6 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 705-713 | |
| P577 | publication date | 2010-12-28 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | Experimental surgical therapies for Huntington's disease | |
| P478 | volume | 17 | |